189 related articles for article (PubMed ID: 34598060)
1. Prioritising breast cancer theranostics: A current medical longing in oncology.
Pandey PN; Saini N; Sapre N; Kulkarni DA; Tiwari DAK
Cancer Treat Res Commun; 2021; 29():100465. PubMed ID: 34598060
[TBL] [Abstract][Full Text] [Related]
2. Scaffolding along nucleic acid duplexes using 2'-amino-locked nucleic acids.
Astakhova IK; Wengel J
Acc Chem Res; 2014 Jun; 47(6):1768-77. PubMed ID: 24749544
[TBL] [Abstract][Full Text] [Related]
3. Perspectives and potential applications of nanomedicine in breast and prostate cancer.
Liu Y; Solomon M; Achilefu S
Med Res Rev; 2013 Jan; 33(1):3-32. PubMed ID: 23239045
[TBL] [Abstract][Full Text] [Related]
4. Macrophage targeted theranostics as personalized nanomedicine strategies for inflammatory diseases.
Patel SK; Janjic JM
Theranostics; 2015; 5(2):150-72. PubMed ID: 25553105
[TBL] [Abstract][Full Text] [Related]
5. Targeted nanotechnologies for cancer intervention: a patent review (2010-2016).
Pradeep P; Kumar P; Choonara YE; Pillay V
Expert Opin Ther Pat; 2017 Sep; 27(9):1005-1019. PubMed ID: 28621571
[TBL] [Abstract][Full Text] [Related]
6. Locked vs. unlocked nucleic acids (LNA vs. UNA): contrasting structures work towards common therapeutic goals.
Campbell MA; Wengel J
Chem Soc Rev; 2011 Dec; 40(12):5680-9. PubMed ID: 21556437
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive approach of hybrid nanoplatforms in drug delivery and theranostics to combat cancer.
Thorat ND; Townley HE; Patil RM; Tofail SAM; Bauer J
Drug Discov Today; 2020 Jul; 25(7):1245-1252. PubMed ID: 32371139
[TBL] [Abstract][Full Text] [Related]
8. Cancer Nanotechnology: A New Revolution for Cancer Diagnosis and Therapy.
Chaturvedi VK; Singh A; Singh VK; Singh MP
Curr Drug Metab; 2019; 20(6):416-429. PubMed ID: 30227814
[TBL] [Abstract][Full Text] [Related]
9. Nanomedicine-based neuroprotective strategies in patient specific-iPSC and personalized medicine.
Jang SF; Liu WH; Song WS; Chiang KL; Ma HI; Kao CL; Chen MT
Int J Mol Sci; 2014 Mar; 15(3):3904-25. PubMed ID: 24599081
[TBL] [Abstract][Full Text] [Related]
10. Targeted Nanotechnology from Bench to Bedside.
Sapalidis K; Kosmidis C; Laskou S; Katsaounis A; Mantalobas S; Passos I; Michalopoulos N; Amaniti A; Sardeli C; Zarogoulidis P
Curr Cancer Drug Targets; 2019; 19(1):3-4. PubMed ID: 30672409
[No Abstract] [Full Text] [Related]
11. Synthetic Lethality: From Research to Precision Cancer Nanomedicine.
Gupta A; Ahmad A; Dar AI; Khan R
Curr Cancer Drug Targets; 2018; 18(4):337-346. PubMed ID: 28669337
[TBL] [Abstract][Full Text] [Related]
12. Meeting the needs of breast cancer: A nucleolin's perspective.
Gregório AC; Lacerda M; Figueiredo P; Simões S; Dias S; Moreira JN
Crit Rev Oncol Hematol; 2018 May; 125():89-101. PubMed ID: 29650282
[TBL] [Abstract][Full Text] [Related]
13. Functionalization of Nanomaterials and Their Application in Melanoma Cancer Theranostics.
Madamsetty VS; Paul MK; Mukherjee A; Mukherjee S
ACS Biomater Sci Eng; 2020 Jan; 6(1):167-181. PubMed ID: 33463233
[TBL] [Abstract][Full Text] [Related]
14. Patent review of novel nanostructrued devices, nanofabrication methods and applications in nanofluidics and nanomedicine.
Michael Chen CY
Recent Pat Nanotechnol; 2012 Jun; 6(2):114-23. PubMed ID: 22181669
[TBL] [Abstract][Full Text] [Related]
15. Radionanomedicine: Advanced Strategy for Precision Theranostics of Breast Cancer.
Guo Y; Liu X
J Biomed Nanotechnol; 2022 Jan; 18(1):50-60. PubMed ID: 35180899
[TBL] [Abstract][Full Text] [Related]
16. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
17. 2D Nanomaterials for Cancer Theranostic Applications.
Cheng L; Wang X; Gong F; Liu T; Liu Z
Adv Mater; 2020 Apr; 32(13):e1902333. PubMed ID: 31353752
[TBL] [Abstract][Full Text] [Related]
18. Nanotechnology: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(19):1-43. PubMed ID: 23074489
[TBL] [Abstract][Full Text] [Related]
19. Enabling individualized therapy through nanotechnology.
Sakamoto JH; van de Ven AL; Godin B; Blanco E; Serda RE; Grattoni A; Ziemys A; Bouamrani A; Hu T; Ranganathan SI; De Rosa E; Martinez JO; Smid CA; Buchanan RM; Lee SY; Srinivasan S; Landry M; Meyn A; Tasciotti E; Liu X; Decuzzi P; Ferrari M
Pharmacol Res; 2010 Aug; 62(2):57-89. PubMed ID: 20045055
[TBL] [Abstract][Full Text] [Related]
20. Theranostics in Nuclear Medicine: Emerging and Re-emerging Integrated Imaging and Therapies in the Era of Precision Oncology.
Gomes Marin JF; Nunes RF; Coutinho AM; Zaniboni EC; Costa LB; Barbosa FG; Queiroz MA; Cerri GG; Buchpiguel CA
Radiographics; 2020 Oct; 40(6):1715-1740. PubMed ID: 33001789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
